TRIPLE NEGATIVE BREAST CANCER

This early-phase study tested a new treatment called BT-001, which is injected directly into tumors. It was given alone and combined with an existing immunotherapy drug (pembrolizumab) to people with advanced cancers that had spread. The main goals were to find a safe dose and se…

This study tested an experimental drug called VLS-101 (zilovertamab vedotin) in 102 people with advanced solid tumors that had spread and stopped responding to previous treatments. The trial aimed to see if the drug could shrink tumors and was safe for cancers including breast, l…

This early-stage study tested a new oral cancer drug called NUV-868, both alone and combined with existing medications (olaparib or enzalutamide), in adults with advanced solid tumors. The trial aimed to find safe doses and see if these treatments could help control cancers that …

This was a first-in-human study to test the safety and find the right dose of a new immunotherapy drug called FAZ053. It was given alone and in combination with another drug, PDR001, to 154 adults with advanced solid tumors that had stopped responding to standard treatments. The …

This study tested whether combining two immunotherapy drugs could help control several types of advanced cancer. It involved 77 people with cancers like skin cancer, lung cancer, and breast cancer. The trial was terminated early because the drug supply was discontinued, so resear…

This study tested if giving an immunotherapy drug (atezolizumab) alone for two weeks before starting standard chemotherapy was better than starting both treatments together. It involved 442 people with triple-negative breast cancer, a hard-to-treat type, before they had surgery. …

This was an early-stage study testing a new drug called BDC-3042, both by itself and combined with an existing immunotherapy (cemiplimab), in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find safe doses and see if the tre…

This early-phase study tested a new drug called PRO1107 in patients with advanced solid tumors that had stopped responding to other treatments. The main goals were to find a safe dose and see if the drug could shrink tumors in cancers like ovarian, lung, breast, and others. The s…

This early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…

This early-stage study tested a new drug called OC-001, both by itself and combined with an existing immunotherapy drug, in people with various advanced cancers that had stopped responding to standard treatments. The main goal was to check the safety of the drug and see how the b…

This study tested a combination of three treatments for an aggressive type of breast cancer that had stopped responding to standard chemotherapy. It combined chemotherapy (docetaxel), an immunotherapy drug (pembrolizumab), and an experimental gene therapy designed to boost the im…

This study tested whether combining two drugs, ZEN003694 and talazoparib, could help control triple-negative breast cancer in patients whose cancer had progressed despite prior treatments. The trial involved 115 adults with advanced disease who had not responded to previous thera…

This study tested whether adding an experimental drug called magrolimab to standard chemotherapy could better control advanced triple-negative breast cancer. Researchers enrolled 92 patients with cancer that couldn't be surgically removed and had spread locally or to other body p…